{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T00:19:20Z","timestamp":1790036360666,"version":"4.0.1"},"reference-count":45,"publisher":"International Heart Journal (Japanese Heart Journal)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int. Heart J."],"published-print":{"date-parts":[[2017]]},"DOI":"10.1536\/ihj.16-547","type":"journal-article","created":{"date-parts":[[2017,9,29]],"date-time":"2017-09-29T22:11:24Z","timestamp":1506723084000},"page":"778-786","source":"Crossref","is-referenced-by-count":14,"title":["DPP4 Inhibition Ameliorates Cardiac Function by Blocking the Cleavage of HMGB1 in Diabetic Mice After Myocardial Infarction"],"prefix":"10.1536","volume":"58","author":[{"given":"Akihiko","family":"Sato","sequence":"first","affiliation":[{"name":"Department of Cardiovascular Medicine, Fukushima Medical University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Suzuki","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Fukushima Medical University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shunsuke","family":"Watanabe","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Fukushima Medical University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Shimizu","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Fukushima Medical University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuichi","family":"Nakamura","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Fukushima Medical University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomofumi","family":"Misaka","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Fukushima Medical University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuro","family":"Yokokawa","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Fukushima Medical University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuro","family":"Shishido","sequence":"additional","affiliation":[{"name":"First Department of Internal Medicine, Yamagata University School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shu-ichi","family":"Saitoh","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Fukushima Medical University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takafumi","family":"Ishida","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Fukushima Medical University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isao","family":"Kubota","sequence":"additional","affiliation":[{"name":"First Department of Internal Medicine, Yamagata University School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuchika","family":"Takeishi","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Fukushima Medical University"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"437","reference":[{"key":"1","doi-asserted-by":"publisher","unstructured":"1. Roger VL, Go AS, Lloyd-Jones DM, <i>et al<\/i>. Heart disease and stroke statistics-2012 update: a report from the American Heart Association. Circulation 2012; 125: e2-e220.","DOI":"10.1161\/CIR.0b013e31823ac046"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Miura T, Miki T. Limitation of myocardial infarct size in the clinical setting: current status and challenges in translating animal experiments into clinical therapy. Basic Res Cardiol 2008; 103: 501-13. (Review)","DOI":"10.1007\/s00395-008-0743-y"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Hausenloy DJ, Yellon DM. Targeting myocardial reperfusion injury-The Search Continues. N Engl J Med 2015; 373: 1073-5.","DOI":"10.1056\/NEJMe1509718"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Heusch G. Molecular basis of cardioprotection: signal transduction in ischemic pre-, post-, and remote conditioning. Circ Res 2015; 116: 674-99. (Review)","DOI":"10.1161\/CIRCRESAHA.116.305348"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Thomas JO, Stott K. H1 and HMGB1: modulators of chromatin structure. Biochem Soc Trans 2012; 40: 341-6. (Review)","DOI":"10.1042\/BST20120014"},{"key":"6","doi-asserted-by":"publisher","unstructured":"6. Aizawa S, Nishino H, Saito K, Kimura K, Shirakawa H, Yoshida M. Stimulation of transcription in cultured cells by high mobility group protein 1: essential role of the acidic carboxyl-terminal region. Biochemistry 1994; 33: 14690-5.","DOI":"10.1021\/bi00253a006"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Thomas JO, Travers AA. HMG1 and 2, and related &apos;architectural&apos; DNA-binding proteins. Trends Biochem Sci 2001; 26: 167-74. (Review)","DOI":"10.1016\/S0968-0004(01)01801-1"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Yang H, Antoine DJ, Andersson U, Tracey KJ. The many faces of HMGB1: molecular structure-functional activity in inflammation, apoptosis, and chemotaxis. J Leukoc Biol 2013; 93: 865-73. (Review)","DOI":"10.1189\/jlb.1212662"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Yang H, Wang H, Czura CJ, Tracey KJ. The cytokine activity of HMGB1. J Leukoc Biol 2005; 78: 1-8. (Review)","DOI":"10.1189\/jlb.1104648"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Erlandsson Harris H, Andersson U. Mini-review: The nuclear protein HMGB1 as a proinflammatory mediator. Eur J Immunol 2004; 34: 1503-12. (Review)","DOI":"10.1002\/eji.200424916"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Naglova H, Bucova M. HMGB1 and its physiological and pathological roles. Bratisl Lek Listy 2012; 113: 163-71. (Review)","DOI":"10.4149\/BLL_2012_039"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Kitahara T, Takeishi Y, Harada M, <i>et al<\/i>. High mobility group box 1 restores cardiac function after myocardial infarction in transgenic mice. Cardiovasc Res 2008; 80: 40-6.","DOI":"10.1093\/cvr\/cvn163"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Kohno T, Anzai T, Naito K, <i>et al<\/i>. Role of high-mobility group box 1 protein in post-infarction healing process and left ventricular remodelling. Cardiovasc Res 2009; 81: 565-73.","DOI":"10.1093\/cvr\/cvn291"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Nakamura Y, Suzuki S, Shimizu T, <i>et al<\/i>. High Mobility Group Box 1 Promotes Angiogenesis from Bone Marrow-derived Endothelial Progenitor Cells after Myocardial Infarction. J Atheroscler Thromb 2015; 22: 570-81.","DOI":"10.5551\/jat.27235"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Lamblin N, Fertin M, de Groote P, Bauters C. Cardiac remodeling and heart failure after a first anterior myocardial infarction in patients with diabetes mellitus. J Cardiovasc Med (Hagerstown) 2012; 13: 353-9.","DOI":"10.2459\/JCM.0b013e328353694b"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Zhong J, Maiseyeu A, Davis SN, Rajagopalan S. DPP4 in cardiometabolic disease: recent insights from the laboratory and clinical trials of DPP4 inhibition. Circ Res 2015; 116: 1491-504.","DOI":"10.1161\/CIRCRESAHA.116.305665"},{"key":"17","doi-asserted-by":"publisher","unstructured":"17. Manucci E, Pala L, Ciani S, <i>et al<\/i>. Hyperglycaemia increases dipeptidyl peptidase IV activity in diabetes mellitus. Diabetologia 2005; 48: 1168-72.","DOI":"10.1007\/s00125-005-1749-8"},{"key":"18","doi-asserted-by":"publisher","unstructured":"18. Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase 4 inhibitors in type 2 diabetes. Lancet 2006; 368: 1696-705. (Review)","DOI":"10.1016\/S0140-6736(06)69705-5"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Koska J, Sands M, Burciu C, Reaven P. Cardiovascular effects of dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes. Diab Vasc Dis Res 2015; 12: 154-63. (Review)","DOI":"10.1177\/1479164114562411"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Marchetii C, Di Carlo A, Facchiano F, <i>et al<\/i>. High mobility group box 1 is a novel substrate of dipeptidyl peptidase-IV. Diabetologia 2012; 55: 236-44.","DOI":"10.1007\/s00125-011-2213-6"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Biscetti F, Straface G, De Cristofaro R, <i>et al<\/i>. High-mobility group box-1 protein promotes angiogenesis after peripheral ischemia in diabetic mice through a VEGF-dependent mechanism. Diabetes 2010; 59: 1496-505.","DOI":"10.2337\/db09-1507"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Hirano T, Yamashita S, Takahashi M, Hashimoto H, Mori Y, Goto M. Anagliptin, a dipeptidyl peptidase-4 inhibitor, decreases macrophage infiltration and suppresses atherosclerosis in aortic and coronary arteries in cholesterol-fed rabbits. Metabolism 2016; 65: 893-903.","DOI":"10.1016\/j.metabol.2016.03.010"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Nakaya K, Kubota N, Takamoto I, <i>et al<\/i>. Dipeptidyl peptidase-4 inhibitor anagliptin ameliorates diabetes in mice with haploinsufficiency of glucokinase on a high-fat diet. Metabolism 2013; 62: 939-51.","DOI":"10.1016\/j.metabol.2013.01.010"},{"key":"24","doi-asserted-by":"publisher","unstructured":"24. Ervinna N, Mita T, Yasunari E, <i>et al<\/i>. Anagliptin, a DPP-4 inhibitor, suppresses proliferation of vascular smooth muscles and monocyte inflammatory reaction and attenuates atherosclerosis in male apo E-deficient mice. Endocrinology 2013; 154: 1260-70.","DOI":"10.1210\/en.2012-1855"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Mulvihill EE, Varin EM, Ussher JR, <i>et al<\/i>. Inhibition of Dipeptidyl Peptidase-4 Impairs Ventricular Function and Promotes Cardiac Fibrosis in High Fat-Fed Diabetic Mice. Diabetes 2016; 65: 742-54.","DOI":"10.2337\/db15-1224"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Lamont BJ, Drucker DJ. Differential antidiabetic efficacy of incretin agonists versus DPP-4 inhibition in high fat fed mice. Diabetes 2008; 57: 190-8.","DOI":"10.2337\/db07-1202"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27. Miyata M, Suzuki S, Misaka T, <i>et al<\/i>. Senescence marker protein 30 has a cardio-protective role in doxorubicin-induced cardiac dysfunction. PLoS One 2013; 8: e79093.","DOI":"10.1371\/journal.pone.0079093"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28. Read CM, Cary PD, Crane-Robinson C, Driscoll PC, Norman DG. Solution structure of a DNA-binding domain from HMG1. Nucleic Acid Res 1993; 21: 3427-36.","DOI":"10.1093\/nar\/21.15.3427"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29. Stros M. HMGB proteins: interactions with DNA and chromatin. Biochim Biophys Acta 2010; 1799: 101-13. (Review)","DOI":"10.1016\/j.bbagrm.2009.09.008"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30. Bianchi ME, Beltrame M. Upwardly mobile proteins. Workshop: the role of HMG proteins in chromatin structure, gene expression and neoplasia. EMBO Rep 2000; 1: 109-14.","DOI":"10.1093\/embo-reports\/kvd030"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31. Calogero S, Grassi F, Aguzzi A, <i>et al<\/i>. The lack of chromosomal protein Hmg1 does not disrupt cell growth but causes lethal hypoglycaemia in newborn mice. Nat Genet 1999; 22: 276-80.","DOI":"10.1038\/10338"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32. Ellerman JE, Brown CK, de Vera M, <i>et al<\/i>. Masquerader: high mobility group box-1 and cancer. Clin Cancer Res 2007; 13: 2836-48. (Review)","DOI":"10.1158\/1078-0432.CCR-06-1953"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33. Lotze MT, Tracey KJ. High-mobility group box 1 protein (HMGB1): nuclear weapon in the immune arsenal. Nat Rev Immunol 2005; 5: 331-42. (Review)","DOI":"10.1038\/nri1594"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34. van Beijnum JR, Nowak-Sliwinska P, van den Boezem E, Hautvast P, Buurman WA, Griffioen AW. Tumor angiogenesis is enforced by autocrine regulation of high-mobility group box 1. Oncogene 2013; 32: 363-74.","DOI":"10.1038\/onc.2012.49"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35. van Beijnum JR, Dings RP, van der Linden E, <i>et al<\/i>. Gene expression of tumor angiogenesis dissected: specific targeting of colon cancer angiogenic vasculature. Blood 2006; 108: 2339-48.","DOI":"10.1182\/blood-2006-02-004291"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36. Straino S, Di Carlo A, Mangoni A, <i>et al<\/i>. High-mobility group box 1 protein in human and murine skin: involvement in wound healing. J Invest Dermatol 2008; 128: 1545-53.","DOI":"10.1038\/sj.jid.5701212"},{"key":"37","doi-asserted-by":"publisher","unstructured":"37. Sauv\u00e9 M, Ban K, Momen MA, <i>et al<\/i>. Genetic Deletion or pharmacological inhibition of dipeptidyl peptidase-4 improves cardiovascular outcomes after myocardial infarction in mice. Diabetes 2010; 59: 1063-73.","DOI":"10.2337\/db09-0955"},{"key":"38","doi-asserted-by":"publisher","unstructured":"38. Shigeta T, Aoyama M, Bando YK, <i>et al<\/i>. Dipeptidyl peptidase-4 modulates left ventricular dysfunction in chronic heart failure via angiogenesis-dependent and -independent actions. Circulation 2012; 126: 1838-51.","DOI":"10.1161\/CIRCULATIONAHA.112.096479"},{"key":"39","doi-asserted-by":"crossref","unstructured":"39. Scirica BM, Bhatt DL, Braunwald E, <i>et al<\/i>. Saxagliptin and cardiovascular outcome in patients with type 2 diabetes mellitus. N Eng J Med 2013; 369: 1317-26.","DOI":"10.1056\/NEJMoa1307684"},{"key":"40","doi-asserted-by":"crossref","unstructured":"40. White WB, Cannon CP, Heller SR, <i>et al<\/i>. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Eng J Med 2013; 369: 1327-35.","DOI":"10.1056\/NEJMoa1305889"},{"key":"41","doi-asserted-by":"crossref","unstructured":"41. Green JB, Bethel MA, Armstrong PW, <i>et al<\/i>. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N Eng J Med 2015; 373: 232-42.","DOI":"10.1056\/NEJMoa1501352"},{"key":"42","doi-asserted-by":"crossref","unstructured":"42. Scirica BM, Braunwald E, Raz I, <i>et al<\/i>. Heart failure, saxagliptin, and diabetes mellitus: observations from the SAVOR-TIMI 53 randomized trial. Circulation 2014; 130: 1579-88.","DOI":"10.1161\/CIRCULATIONAHA.114.010389"},{"key":"43","doi-asserted-by":"crossref","unstructured":"43. Zannad F, Cannon CP, Cushman WC, <i>et al<\/i>. Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial. Lancet 2015; 385: 2067-76.","DOI":"10.1016\/S0140-6736(14)62225-X"},{"key":"44","doi-asserted-by":"crossref","unstructured":"44. McGuire DK, Vav de Werf F, Armstrong PW, <i>et al<\/i>. Association Between Sitagliptin Use and Heart Failure Hospitalization and Related Outcomes in Type 2 Diabetes Mellitus: Secondary Analysis of a Randomized Clinical Trial. JAMA Cardiol 2016; 1: 126-35.","DOI":"10.1001\/jamacardio.2016.0103"},{"key":"45","doi-asserted-by":"crossref","unstructured":"45. Kubota A, Takano H, Wang H, <i>et al<\/i>. DPP-4 inhibition has beneficial effects on the heart after myocardial infarction. J Moll Cell Cardiol 2016; 91: 72-80.","DOI":"10.1016\/j.yjmcc.2015.12.026"}],"container-title":["International Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/ihj\/58\/5\/58_16-547\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,26]],"date-time":"2023-08-26T16:10:34Z","timestamp":1693066234000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/ihj\/58\/5\/58_16-547\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017]]},"references-count":45,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2017]]}},"URL":"https:\/\/doi.org\/10.1536\/ihj.16-547","relation":{},"ISSN":["1349-2365","1349-3299"],"issn-type":[{"value":"1349-2365","type":"print"},{"value":"1349-3299","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017]]}}}